Garadacimab Approved to Prevent Angioedema Attacks
24 January 2025 GOV.UK
Garadacimab (andembry) has been approved for the prevention of angioedema attacks in adults and adolescents (12 years and older) with hereditary angioedema (HAE).
HAE is a rare, genetic condition that causes episodes of swelling (angioedema) in various body parts, including the face, limbs, abdomen, and throat. These attacks can be triggered by a variety of factors, including stress, certain medications, and hormonal changes.
Garadacimab is a human monoclonal antibody that targets plasma kallikrein, a protein that is involved in the body’s inflammation response. By inhibiting plasma kallikrein, garadacimab prevents the formation of bradykinin, a molecule that is responsible for the symptoms of angioedema.
In clinical trials, garadacimab has been shown to be effective in reducing the frequency and severity of angioedema attacks. In one study, patients receiving garadacimab experienced a 70% reduction in the number of attacks compared to placebo.
Garadacimab is given as a subcutaneous injection every two weeks. The recommended dose is 600 mg.
The most common side effects of garadacimab include injection site reactions, headache, and fatigue.
Garadacimab is a new treatment option that can help to prevent angioedema attacks in people with HAE. It is a well-tolerated and effective medication that can significantly improve the quality of life for people with this condition.
For more information:
- Garadacimab (andembry) Prescribing Information
- Hereditary Angioedema
- Garadacimab: A New Treatment for Hereditary Angioedema
Garadacimab (andembry) approved to prevent angioedema attacks
The AI has provided us with the news.
I’ve asked Google Gemini the following question, and here’s its response.
GOV UK a new article on 2025-01-24 12:29 titled “Garadacimab (andembry) approved to prevent angioedema attacks”. Please write a detailed article on this news item, including any relevant information. Answers should be in English.
94